reports
Galapagos creëert nieuwe inschrijvingsrechtenplannen
Galapagos creëert nieuwe inschrijvingsrechtenplannen Mechelen, België; 16 mei 2024; 22:01 CET ; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt vandaag aan dat haar Raad van Bestuur 1.614.000 inschrijvingsrechten heeft gecreëerd onder nieuwe inschrijvingsrechtenplannen ten gunste van bepaalde leden van het personeel van de vennootschap en haar dochtervennootschappen. De Raad van Bestuur van Galapagos heeft op 16 mei 2024 “Inschrijvingsrechtenplan 2024 BE”, bestemd voor de personeelsleden van de vennootschap, “Inschrijvingsrechtenplan 2024 RMV”, bestemd voor d...
Galapagos creates new subscription right plans
Galapagos creates new subscription right plans Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 16 May 2024, the Board of Directors of Galapagos approved “Subscription Right Plan 2024 BE”, intended for members of personnel of the company, “Subscription Right Plan 2024 RMV,” intended for the employees of its French subsidiary, Ga...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Sharad Kumar S.P
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Galapagos Unlocks scalability potential of POC CAR-Ts with BCA US coll...
Galapagos announced a collaboration with Blood Centers of America (BCA), gaining access to BCA's network of >50 sites in the US for the decentralised manufacturing (POC) of Galapagos' CAR-T cell therapies (financial details not disclosed). We believe this collaboration could unlock significant manufacturing capacity for Galapagos in the US, and our back of the envelope calculation points to a capacity of 8K CAR-Ts per year with just 4 Cocoon's in each site – this comes close to Gilead's 2024 glo...
Galapagos and Blood Centers of America announce strategic collaboratio...
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S. BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centersCollaboration enables rapid deployment of Galapagos' decentralized CAR-T platform across the U.S., improving patient access to potentially life-saving CAR-T treatmentsImportant milestone for Galapagos' U.S. expansion strategy, supporting upcoming pivotal trials and potential future...
Galapagos en Blood Centers of America kondigen een strategische samenw...
Galapagos en Blood Centers of America kondigen een strategische samenwerking aan om Galapagos' gedecentraliseerde CAR-T productienetwerk in de VS versneld op te schalen BCA's nationale netwerk van bloedcentra zal gedecentraliseerde productiediensten leveren voor Galapagos’ CAR-T productkandidaten, dichtbij centra voor kankerbehandelingenDe samenwerking maakt snelle inzet van Galapagos' gedecentraliseerde CAR-T-platform in de VS mogelijk, waardoor de toegang tot potentieel levensreddende CAR-T-behandelingen voor patiënten verbetertBelangrijke mijlpaal voor Galapagos' expansiestrategie in de ...
- Jerôme Bodin
ODDO BHF Small & MIDCAP MORNING NEWS - 03/05/2024
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
- Jerôme Bodin
ODDO BHF Small & MIDCAP MORNING NEWS - 05/03/2024
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
- Damien Choplain
- Martial Descoutures
Galapagos : Largely unsurprising numbers
>Solid cash position - Galapagos reported its Q1 earnings after the close in the US. Group revenues came in at € 100m vs € 83m expected. The bulk stemmed from its agreement with Gilead for € 62m while net product sales amounted to € 37m. At the operating level, costs were broadly under control, with total expenditure of around € 129m vs € 110m although we note an increase of close to 36% in R&D expense due to the development of the clinical portfolio. In contrast...
- Damien Choplain
- Martial Descoutures
Galapagos : Une publication sans grande surprise
>Une trésorerie solide - Galapagos publiait après la fermeture du marché US ses résultats du T1. Les revenus du groupe ressortent ainsi à 100 M€ vs 83 M€ att. L’essentiel des revenus vient de son accord avec Gilead pour 62 M€ alors que les ventes des produits nets ressortent à 37 M€. Au niveau opérationnel, les coûts sont globalement bien maitrisés ce qui conduit à avoir des dépenses totales de l’ordre de 129 M€ vs 110 M€ même si nous observons une hausse de près...
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Sharad Kumar S.P
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Galapagos FIRST LOOK: uneventful 1Q24 results, FY24 cash burn guidance...
Galapagos reported uneventful 1Q24 results and confirmed its FY24 cash burn guidance of € 280-320m (FY23: € 414.8m), thanks to the savings from the transfer of Jyseleca to Alfasigma. While the company did not provide an update on timelines for its pipeline, we think data updates from the phase 1/2 CAR-T trials in r/r NHL and r/r CLL could come at upcoming scientific conferences (e.g. ASH in December 2024). Beyond that, BD remains on the table and we'd like to see an acceleration on that front wi...
- Francesca Ferragina
Aedifica/Portfolio stabilisation is good/BUY
The year has started well with a top line organic growth of 3.3% and bottom line EPRA earnings increase of 8% in 1Q. LTV is safe at 39.6% (we would not be surprised to see the company finalising an acquisition). Aedifica stated that these results were a bit ahead of its internal budget and we confirm our current estimates, which are in line with latest guidance. What we like most about this set of results is the small positive LFL revaluation of the portfolio, positive for the first time in five...
- David Seynnaeve
- PhD
Galapagos - Q1 24 results
GLPG published its Q1 results, reporting Group net revenues of EUR 100m, in line with CSS. Net profit was significantly up (but below CSS), notably boosted by preliminary calculation of the gain on the sale of Jyseleca.FY24 reduced cash burn guidance reiterated. Nothing new on the CAR-T front. Yet, it is good to see that the company still plans to submit IND applications for its CAR-Ts still in 2024. Remember that GLPG has been running CAR-T trials in Europe only so far.Overall, no material surp...
Galapagos reports first quarter 2024 financial results
Galapagos reports first quarter 2024 financial results Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier MedicinesTransferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areasGroup net revenues in the first quarter of €100 millionCash and current financial investments of €3.6 billion on 31 March 2024Reconfirmed 2024 cash burni guidance o...
Galapagos rapporteert financiële resultaten voor het eerste kwartaal 2...
Galapagos rapporteert financiële resultaten voor het eerste kwartaal 2024 Vooruitgang met potentiële best-in-class R&D pijplijn van celtherapie en kleine moleculen, met vier klinische assets en >15 onderzoeksprogramma's in oncologie en immunologie Overeenkomsten afgesloten met BridGene Biosciences en Thermo Fisher Scientific, en investering in Frontier MedicinesJyseleca® business overgedragen aan Alfasigma S.p.A., waardoor middelen vrijkomen om te investeren in groeigebiedenNetto groepsomzet in het eerste kwartaal van €100 miljoenGeldmiddelen en kortlopende financiële investeringen van €...
- Jean Danjou
- Oliver Metzger
- Thomas Zlowodzki
A1XEH4 CROSSJECT SA
TFI TELEVISION FRANCAISE 1 SA
ISS ISS A/S
NRG NRJ GROUP SA
ALTA ALTAREA SCA
BOSS HUGO BOSS AG
G24 SCOUT24 AG
BAMNB KONINKLIJKE BAM GROEP NV
GLB GLANBIA PLC
SAVE SAVENCIA SA
FIE FIELMANN AG
VID VIDRALA SA
VLK VAN LANSCHOT KEMPEN NV CERT. OF SHS
AED AEDIFICA SA
BEZ BERENTZEN GRUPPE
WAF SILTRONIC AG
TWEKA TKH GROUP N.V. CERT
OREGE OREGE SA
LNSX SIXT LEASING AG
FFARM FORFARMERS
MVC METROVACESA SA
VOS VOSSLOH AG
NEOEN NEOEN S.A.
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
TE TECHNIP ENERGIES NV
C3RY CHERRY AG
- Jean Danjou
- Oliver Metzger
- Thomas Zlowodzki
ODDO BHF Small & MIDCAP MORNING NEWS - 02/05/2024
Nous sortons GALP de notre liste ODDO BHF European Large Caps. La valeur a réalisé une performance de +31,3% depuis son entrée le 20 mars dernier. Notre analyste adopte ce jour une opinion Neutre (vs Surperformance) sur la valeur qui a atteint notre objectif de cours. - ...
A1XEH4 CROSSJECT SA
TFI TELEVISION FRANCAISE 1 SA
ISS ISS A/S
NRG NRJ GROUP SA
ALTA ALTAREA SCA
BOSS HUGO BOSS AG
G24 SCOUT24 AG
BAMNB KONINKLIJKE BAM GROEP NV
GLB GLANBIA PLC
SAVE SAVENCIA SA
FIE FIELMANN AG
VID VIDRALA SA
VLK VAN LANSCHOT KEMPEN NV CERT. OF SHS
AED AEDIFICA SA
BEZ BERENTZEN GRUPPE
WAF SILTRONIC AG
TWEKA TKH GROUP N.V. CERT
OREGE OREGE SA
LNSX SIXT LEASING AG
FFARM FORFARMERS
MVC METROVACESA SA
VOS VOSSLOH AG
NEOEN NEOEN S.A.
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
TE TECHNIP ENERGIES NV
C3RY CHERRY AG
- Gerardo Ibanez
- Steven Boumans
Aedifica SA : Q1 2024 results: Stable fair values after five quarters ...
>Outlook reiterated, stable fair values, negative rent negotiations and pipeline continues to decline - FY2024 outlook EPRA EPS 4.70 or €223m EPRA earnings reiterated.Rental income +3.3% on a like-for-like basis (FY2023: 5.2% and 3% in FY2024 budget) broken down by +3.4% indexation, -0.7% rent negotiations and +0.6% fx changes.Fair value of investment portfolio increased +0.02%, after five consecutive quarters of negative portfolio valuations. Belgian (-0.5%...
- ING Helpdesk
Benelux Morning Notes
Aedifica: First sign of portfolio valuation stabilization. ArcelorMittal: Solid 1Q24 EBITDA beat, softer FCF reflects WC and CAPEX phasing. Belgian telcos: Peer Telenet 1Q24 results, still weak commercial performance. dsm-firmenich AG: Vita-still not-min. IBA: Contract to install a P1 system in Connecticut. KPN: VodafoneZiggo 1Q24 results confirm fixed losses, mobile weaker QoQ. Shell plc: Good start to the year
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.